NRX Pharmaceuticals (NRXP) Amortization of Deferred Charges (2025 - 2026)
NRX Pharmaceuticals' (NRXP) quarterly Amortization of Deferred Charges came in at $102000.0 in Q1 2026, up 75.86% on a QoQ basis from $58000.0 in Q4 2025.
NRX Pharmaceuticals (NRXP) Amortization of Deferred Charges (2025 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has 2 years of Amortization of Deferred Charges data on file, last reported at $102000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges changed N/A year-over-year to $102000.0 in Q1 2026; TTM through Mar 2026 was $167000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $73000.0, changed N/A from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $102000.0, up from $58000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for NRXP reached as high as $102000.0 in Q1 2026 and fell as low as $7000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn |
| 10 | NRX Pharmaceuticals | 118.15 Mn | 111.45 Mn | 437,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 102,000.00 |
| Mar 31, 2026 | 102,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Dec 31, 2025 | 58,000.00 |
| Sep 30, 2025 | 7,000.00 |
| Sep 30, 2025 | 7,000.00 |